Journal
CLINICAL NEUROLOGY AND NEUROSURGERY
Volume 113, Issue 5, Pages 350-357Publisher
ELSEVIER
DOI: 10.1016/j.clineuro.2010.09.016
Keywords
Acid alpha-glucosidase; Dynamometer; Enzyme replacement therapy; Glycogenosis type II; Isometric tourque measurement; Pompe disease
Categories
Funding
- German Research Council [SFB/TR3 TP A7]
- Foundation of Medical Research, Frankfurt
Ask authors/readers for more resources
Objective: Late-onset Pompe disease is a slowly progressive disorder resulting from deficiency of lysosomal acid alpha-glucosidase (GAA). Since 2006, an intravenous enzyme replacement therapy (ERT) with Myozyme (TM) (alglucosidase alfa) is available but long-term experience with ERT in late-onset Pompe disease is still limited. Methods: Two adult patients with impaired walking ability and disease duration of 10 and 13 years, respectively received ERT over a period of 24 months. Clinical and functional parameters including dynamometer-based assessment of proximal muscle strength were registered longitudinally. Results: In both patients some gain in function and physical endurance could be observed which was collaborated by stable dynamometer tests. No serious adverse events occurred and no patient required de novo ventilation. Conclusion: The clinical results from our data base imply that long term enzyme replacement therapy seems to somewhat affect functionality and quality of life and can stabilize the otherwise progressive disease course in patients with late-onset Pompe disease. (C) 2010 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available